Thermo Fisher Scientific Inc. continues to expand global capacity and capabilities across its pharma services network to support government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments. The company is now supporting more than 200 of these projects globally.

In the U.S., the Biomedical Advanced Research and Development Authority (BARDA), announced funding to support the expansion of Thermo Fisher’s manufacturing capacity for sterile injectables, which can be used to fill a high volume of vaccine doses. Thermo Fisher is also supporting multiple vaccine programs globally that are in or entering human clinical trials, providing critical capacity and expertise that has accelerated development and readiness.

The company has also expanded capacity for customers developing new and existing therapies, including promising anti-viral drugs, to meet increased demand and enable biopharma customers to compress timelines for delivery to patients. Through accelerated manufacturing of a common anti-inflammatory treatment to relieve COVID-19 symptoms, Thermo Fisher produced and distributed a year’s worth of medicine in just a few months, helping to meet a surge in hospital demand.

In addition to its work on COVID-19-related vaccines and therapies, the company continues to ensure that patients undergoing clinical trials continue to receive the medicines they need. A “site to patient” program, launched at the start of the pandemic, has helped to ensure clinical trial patients have uninterrupted access to life-saving investigational drug shipments without having to visit a clinic, one of many efforts to maintain supply chain continuity during the pandemic.